Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.
Direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) has high efficacy and limited toxicity. We hypothesised that efficacy of glecaprevir-pibrentasvir for chronic HCV with a simplified treatment monitoring schedule would be non-inferior to a standard treatment monitoring schedule. In this open-label multicentre phase 3b trial, treatment-naïve adults with chronic HCV without cirrhosis were randomly assigned (2:1) to receive glecaprevir-pibrentasvir 300mg-120mg daily for eight weeks administered with a simplified or standard monitoring strategy. Clinic visits occurred at baseline and post-treatment week 12 in the simplified arm, and at baseline, week four, week eight, and post-treatment week 12 in the standard arm. Study nurse phone contact occurred at week four and week eight in both arms. Participants requiring adherence support were not eligible, including those reporting recent injecting drug use. The primary endpoint was sustained virological response at post-treatment week 12 (SVR12), with a non-inferiority margin of 6%. Overall, 380 participants (60% male, 47% genotype 1, 32% genotype 3) with chronic HCV were randomized and treated with glecaprevir-pibrentasvir in the simplified (n=253) and standard (n=127) arms. In the intention-to-treat population, SVR12 was 92% (95% CI 89%, 95%) in the simplified and 95% (95%CI 92%, 99%) in the standard arm (difference between arms, -3.2%; 95%CI -8.2%, 1.8%), and did not reach non-inferiority. In the per-protocol population, SVR12 was 97% (95%CI 96%, 99%) in the simplified and 98% (95%CI, 96%, 100%) in the standard arm. No treatment-related serious adverse events were reported. In patients with chronic HCV infection without cirrhosis, treatment with glecaprevir-pibrentasvir was safe and effective. In comparison to standard monitoring, a simplified monitoring schedule did not achieve non-inferiority. Direct-acting antiviral (DAA) therapy for hepatitis C is highly effective and well tolerated. The SMART-C randomised trial evaluated an eight-week regimen of glecaprevir-pibrentasvir for hepatitis C therapy using a simplified monitoring schedule that included no pathology tests or clinic visits during treatment. This simplified strategy produced a high cure rate (92%), but was not equivalent to the standard monitoring schedule cure rate (95%).